{"id":"tazarotene-0-045-lotion","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Skin irritation (erythema, burning, pruritus)"},{"rate":"null","effect":"Photosensitivity"},{"rate":"15-25","effect":"Peeling and dryness"},{"rate":"null","effect":"Worsening of acne (retinization)"}]},"_chembl":{"chemblId":"CHEMBL1657","moleculeType":"Small molecule","molecularWeight":"351.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tazarotene is a third-generation retinoid that selectively activates retinoid X receptors (RXR) and retinoid acid receptors (RAR), particularly RAR-beta and RAR-gamma. This activation modulates gene transcription involved in cell differentiation, proliferation, and inflammatory responses in the skin. The drug normalizes keratinization and reduces inflammatory cytokine production, making it effective for treating psoriasis and acne.","oneSentence":"Tazarotene is a retinoid that binds to retinoid receptors to regulate gene expression and reduce skin inflammation and abnormal keratinocyte differentiation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:38:23.232Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Plaque psoriasis"},{"name":"Acne vulgaris"}]},"trialDetails":[{"nctId":"NCT05203315","phase":"PHASE3","title":"Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults","status":"COMPLETED","sponsor":"Austin Institute for Clinical Research","startDate":"2022-01-13","conditions":"Plaque Psoriasis","enrollment":21},{"nctId":"NCT05872256","phase":"PHASE4","title":"A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis","status":"COMPLETED","sponsor":"Dermatology Consulting Services, PLLC","startDate":"2023-06-01","conditions":"Scalp Psoriasis","enrollment":20},{"nctId":"NCT06042647","phase":"PHASE4","title":"Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis","status":"COMPLETED","sponsor":"Dermatology Consulting Services, PLLC","startDate":"2023-07-13","conditions":"Psoriasis Vulgaris","enrollment":10},{"nctId":"NCT04720105","phase":"PHASE4","title":"Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2020-11-19","conditions":"Palmoplantar Psoriasis, Plaque Psoriasis","enrollment":22},{"nctId":"NCT06015152","phase":"NA","title":"Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2022-08-01","conditions":"Scalp Psoriasis","enrollment":90},{"nctId":"NCT05704114","phase":"PHASE4","title":"Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne","status":"COMPLETED","sponsor":"Dr. Emmy Graber","startDate":"2021-02-01","conditions":"Acne Vulgaris, Post Inflammatory Hyperpigmentation, Post Inflammatory Pigmentation Change","enrollment":20},{"nctId":"NCT05282771","phase":"EARLY_PHASE1","title":"A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries, Inc.","startDate":"2021-04-16","conditions":"Plaque Psoriasis","enrollment":402},{"nctId":"NCT03168321","phase":"PHASE3","title":"A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (301)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2017-06-29","conditions":"Acne Vulgaris","enrollment":813},{"nctId":"NCT03168334","phase":"PHASE3","title":"A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2017-07-11","conditions":"Acne Vulgaris","enrollment":801},{"nctId":"NCT02462083","phase":"PHASE3","title":"Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2015-08-11","conditions":"Plaque Psoriasis","enrollment":555}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Arazlo"],"phase":"marketed","status":"active","brandName":"Tazarotene 0.045% Lotion","genericName":"Tazarotene 0.045% Lotion","companyName":"Dr. Emmy Graber","companyId":"dr-emmy-graber","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tazarotene is a retinoid that binds to retinoid receptors to regulate gene expression and reduce skin inflammation and abnormal keratinocyte differentiation. Used for Plaque psoriasis, Acne vulgaris.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}